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Abstract Previous genome-wide association studies
(GWAS) have shown several risk alleles to be associated
with breast cancer. However, the variants identiﬁed so far
contribute to only a small proportion of disease risk. The
objective of our GWAS was to identify additional novel
breast cancer susceptibility variants and to replicate these
ﬁndings in an independent cohort. We performed a two-
stage association study in a cohort of 3,064 women from
Alberta, Canada. In Stage I, we interrogated 906,600 single
nucleotide polymorphisms (SNPs) on Affymetrix SNP 6.0
arrays using 348 breast cancer cases and 348 controls. We
used single-locus association tests to determine statistical
signiﬁcance for the observed differences in allele fre-
quencies between cases and controls. In Stage II, we
attempted to replicate 35 signiﬁcant markers identiﬁed in
Stage I in an independent study of 1,153 cases and 1,215
controls. Genotyping of Stage II samples was done using
Sequenom Mass-ARRAY iPlex platform. Six loci from
four different gene regions (chromosomes 4, 5, 16 and 19)
showed statistically signiﬁcant differences between cases
and controls in both Stage I and Stage II testing, and also in
joint analysis. The identiﬁed variants were from EDNRA,
ROPN1L, C16orf61 and ZNF577 gene regions. The pre-
sented joint analyses from the two-stage study design were
not signiﬁcant after genome-wide correction. The SNPs
identiﬁed in this study may serve as potential candidate loci
for breast cancer risk in a further replication study in Stage
III from Alberta population or independent validation in
Caucasian cohorts elsewhere.
Introduction
Breast cancer is a heterogeneous disease strongly inﬂu-
enced by genetic, environmental and life-style factors.
Mutations in BRCA1 (Hall et al. 1990) and BRCA2
(Wooster et al. 1995) tumor suppressor genes confer
familial breast cancer risk and account for the high pene-
trance alleles characterized thus far. Subsequently, certain
genes of moderate penetrance such as ATM (Ahmed and
Rahman 2006; Renwick et al. 2006), CHEK2 (Meijers-
Heijboer et al. 2002) and PALB2 (Rahman et al. 2007)
were shown to predispose to breast cancer susceptibility.
However, these genes account only for a small proportion
of genetic risk. Intensive research efforts to identify BRCA-
like genes to explain the breast cancer risk in populations
were not successful, thus invoking a polygenic model of
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in non-familial or sporadic breast cancer cases (Pharoah
et al. 2002; 2008; Smith et al. 2006). The polygenic model
enables identiﬁcation of several common genetic variants
that each individually confers only modest risk effect to the
disease.
Subsequent genome-wide association studies (GWAS)
have identiﬁed several new risk alleles to be associated
with breast cancer (Ahmed et al. 2009; Easton et al. 2007;
Gold et al. 2008; Hunter et al. 2007; Murabito et al. 2007;
Stacey et al. 2007, 2008; Thomas et al. 2009; Zheng et al.
2009), thus lending support to the polygenic model of
disease susceptibility. Most of these studies were con-
ducted in women of European ancestry with the exception
of two studies which investigated the risk alleles in Chinese
(Zheng et al. 2009) and Ashkenazi Jewish (Gold et al.
2008) populations. Nonetheless, it is of continuing impor-
tance to conduct GWAS over ethnically diverse popula-
tions including European ancestry to uncover the full
spectrum of breast cancer susceptibility variants. Such
studies are expected to show both unique variants and
conﬁrm previously reported variants.
We performed a two-stage association study on cohorts
from Alberta, Canada to identify novel loci potentially
associated with breast cancer susceptibility. A prior study
from our group successfully validated several previously
reported low-penetrance alleles in the same study popula-
tion (data not shown). The object of our present GWAS
was to identify novel risk loci, i.e., ones not previously
reported in the literature (Ahmed et al. 2009; Easton et al.
2007; Gold et al. 2008; Hunter et al. 2007; Murabito et al.
2007; Stacey et al. 2007, 2008; Thomas et al. 2009; Zheng
et al. 2009) and to replicate these ﬁndings in an indepen-
dent cohort. Herein, we report six previously unreported
loci signiﬁcantly associated with breast cancer, replicated
in one independent cohort.
Materials and methods
Study population
We accessed information about women in Alberta with
conﬁrmed diagnosis of breast cancer (cases) with no doc-
umented family history in the ﬁrst and second degree rel-
atives and clinicopathological information from the
PolyomX project (PolyomX 2001) and Canadian Breast
Cancer Foundation (CBCF) tumor bank (CBCF 2005),
located at the Cross Cancer Institute, Edmonton, Alberta,
Canada. The province of Alberta has centralized cancer
registry, and all cancer patients receive treatment within
the provincial health care services (Alberta Health
Services, AHS). Patients with banked tissues gave pro-
spective written approval for treatment information and
life-long follow-up subject to ethics approval for the
research studies and strict adherence to the health agency
guidelines on privacy, conﬁdentiality, security of patient
personal information and other identiﬁers associated with
banked specimens in the project database. The PolyomX
project accrued tumor and matching buffy coat samples for
breast and other cancer types during the years 2001–2005
from four regional hospitals in Edmonton. The CBCF
tumor bank was initiated in 2005 in Edmonton and Calgary
to bank tumor specimens and to serve as an open source
bank to provide access to samples and associated clinical
information to cancer researchers in Canada.
The histological subtypes of breast cancer subjects were
predominantly invasive ductal carcinomas, non-metastatic
at presentation, with a median age at diagnosis of 53 years.
Control subjects were age- and gender-matched healthy
women selected from the same geographic region (Alberta,
Canada) and were free of cancer at the time of recruitment
for the study, with no documented family history of breast
cancer in the ﬁrst and second degree relatives. Previous
studies addressed Stage I of the whole genome polymor-
phisms scans with emphasis to positive family history of
breast cancer, ethnic diversity (Chinese or Ashkenazi
Jewish populations) or cases with breast cancer in post-
menopausal women (Easton et al. 2007; Gold et al. 2008;
Hunter et al. 2007; Zheng et al. 2009). Controls were
obtained from an AHS cohort study recruiting up to 50,000
Albertans (age group 35–69 years) willing to provide
extensive health and life-style questionnaires and DNA as
part of the ‘‘Tomorrow Project’’ (Tomorrow Project 2001).
We accessed a subset of these individuals (samples banked
between 2002 and 2008) who consented to participate in
the Tomorrow Project, donated blood and provided
detailed family history of breast cancer. Informed consent
was obtained from each participant included in the research
project, and the study was approved by the institutional
research ethics board. Stage I of this study evaluated 348
breast cancer cases and 348 controls; and Stage II studied a
completely independent group comprising 1,153 cases and
1,215 controls. Cases and controls were predominantly of
Caucasian origin, determined based on the self-completed
ethnicity questionnaires. The blood or buffy coat samples
were retrieved from the PolyomX and Tomorrow projects,
and genomic DNA was extracted for each sample using
commercially available Qiagen
TM (Mississauga, Ontario,
Canada) DNA isolation kits. We quantiﬁed isolated geno-
mic DNA using NanoDrop 2000 spectrophotometer (Wil-
mington, DE, USA), and we adhered to the good practices
for sample quality as recommended by Affymetrix geno-
typing protocols.
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For Stage I, 348 breast cancer cases and 348 controls were
genotyped using the Affymetrix genome-wide Human SNP
Array 6.0, which features 906,600 SNP probes with each
probe represented 4–6 times on the array. Sample pro-
cessing was performed following the protocols provided by
Affymetrix. After labeling of DNA, hybridization and
washing steps, the arrays were scanned using the Gene-
Chip
 Scanner 3000 7G (Santa Clara, CA, USA). Geno-
type data were acquired by genotype calling of samples in
batches of 96 using a default genotyping algorithm (Bird-
seed v2) provided by Affymetrix, as per the recommended
guidelines. For Stage II, 1,153 breast cancer cases and
1,215 controls were genotyped using Sequenom Mass-
ARRAY iPlex technology (Gabriel et al. 2009). Genotyp-
ing services were provided by Genome Quebec Innovation
Centre (Montreal, QC, Canada). The Stage I samples were
then re-genotyped on the Sequenom platform to evaluate
the genotype concordance between the platforms, prior to
replication of select markers in an independent cohort
(Stage II).
We applied the following ﬁlters to the genotype data
prior to the association analysis to minimize false-positive
associations, which helps to increase the overall power of
the study:
1. Individual chip call rate Affymetrix recommends the
chip call rate threshold of [86% for SNP 6.0 arrays.
The sample call rates for the 696 samples were: two
samples in the interval (89, 90], 39 in the interval (90,
95], 480 in the interval (95, 98], and 175 in the interval
(98, 100]. In addition, quality for each sample was
determined by contrast quality control (CQC) as
recommended for the SNP Array 6.0 by the manufac-
turers. CQC is a cluster-based algorithm that is a good
predictor of sample genotyping performance. Intensity
of each spot on the array following hybridization,
washing and scanning along with clustering of data
(based on genotype calls of homozygous wild type,
heterozygotes and variant homozygous) was assessed.
Default average CQC for a sample to be included in
further analysis was set at C1.7. Most of our samples
used in this study had a CQC of[2.0.
2. Deviation from Hardy–Weinberg equilibrium (HWE)
We assessed for deviations from HWE using v
2 test,
with 1 degree of freedom (df). Signiﬁcant deviations
were observed for 30,636 SNPs (3.38% of the 906,600
SNPs) in controls at p\0.001 (user-deﬁned stringent
cut-off). We excluded these SNPs from our association
analysis.
3. SNP call rate Failure to assign genotypes for certain
SNPs in a sample affects the completeness of the data,
the association test results and the replication of the
ﬁndings. Different studies to date had adopted different
cut-off points ranging from 80 to 99.7% (Ahmed et al.
2009;E a s t o ne ta l .2007;G o l de ta l .2008;H u n t e re ta l .
2007;S t a c e ye ta l .2007, 2008; Thomas et al. 2009;
T u r n b u l le ta l .2010; Zheng et al. 2009). We adopted a
stringent call rate cut-off of C99%, which meant elimi-
nating a total of 93,126 SNPs (10.3% of the 906,600
SNPs).
4. Concordance of genotype calls (a) Within Affymetrix
Batch effects of the Affymetrix Birdseed v2 genotype
calling algorithm were assessedby grouping the samples
(348casesand348controls)intobatches(7 9 96plus24
in the eighth), with 96 samples in each batch. To assess
genotype call concordance across batches, we included
randomly selected raw data from the ﬁrst seven batches
(47 cases and 25 controls) to the batch eight to bring the
sample size to 96. The mean genotype concordance rate
for the samples achieved in this analysis was very high
([99.9%).(b)AffymetrixversusSequenomTheSNPsthat
were statistically signiﬁcant (p\0.001) in Stage I on
Affymetrix platform and those that were selected for
replication were re-genotyped in 647 samples (326 cases
and 321 controls) on Sequenom Mass-ARRAY iPlex
platform. We consistently observed high mean genotype
concordancerateof[95%betweenthesetwogenotyping
platforms. (c) Within Sequenom To assess the genotype
concordance within Sequenom platform, 132 replicate
samples (67 cases and 65 controls) were randomly
distributed in each of the 96-well plate assay. The mean
genotype concordance rate of the replicates was again
high at[98.6%. We have also analyzed the sample call
rates for the 2,368 Stage II samples (replication study)
within Sequenom and found that 26 samples were in the
interval (80, 90], 67 in the interval (90, 95], 394 in the
interval (95, 98] and 1,881 in the interval (98, 100].
5. Assessment of population stratiﬁcation We explored
the genetic relatedness of our case–control cohorts
prior to independent validation of loci from GWAS
reported here. Detection and removal of outliers
(population stratiﬁcation) is important to minimize
false-positive ﬁndings. To assess the substructure, we
applied the principal component analysis (PCA)-based
EIGENSTRAT method (Price et al. 2006) embedded
in our statistical software (HelixTree
TM) used for the
data analysis reported here. Using a conservative
threshold of C3 standard deviations away from the
mean on one of the two principal components, we
detected a total of 73 samples (46 cases and 27
controls) as outliers. The detected outliers were
removed from our dataset leaving with 302 cases and
321 controls for further scrutiny.
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We calculated the power assuming an additive model of
genetic inheritance, a minor allele frequency (MAF) of 0.1,
genotype relative risk of 1.2 (based on odds ratio (OR) and
allele frequency estimates from previous GWAS for Cau-
casian population), alpha of 0.05 and determined that our
study cohort has more than 80% power to detect associa-
tions (Klein 2007).
The statistical analysis was conducted using commer-
cially available software, HelixTree
TM. Association anal-
ysis was carried out using the case versus control status as
the binary variable. After ﬁltering out SNPs and samples
(PCA outliers, deviations from HWE and missing values),
a total of 782,838 SNPs and 302 cases/321 controls were
included in the analysis for Stage I of the study. A v
2 test
with 1 df was carried out to determine the allele frequency
differences between cases and controls for all the datasets
reported here. Unconditional logistic regression analysis
was used to estimate the OR and 95% conﬁdence intervals
(CI). A genome-wide correction to correct for multiple
marker testing was applied (Bonferroni method: p\6.4 9
10
-8calculatedfromnominalpvalue of0.05/totalnumberof
markers as 782,838).
Whole genome association analysis from Stage I
enabled us to identify subset of markers with nominal
p values (\0.05) that showed association with the disease
trait. As this subset of markers may also include several
false associations, we attempted to replicate these primary
ﬁndings by testing them on an independent cohort with
higher sample sizes than in Stage I. We selected the
markers for replication from Stage I in a systematic manner
proposed by Zheng et al. (2009). Of the 35,859 markers
from Stage I that showed association with breast cancer
risk (p\0.05) and showed conformity with the HWE
criteria, we selected the ones with p\0.001, MAF[0.1,
distinct genotype clusters and novel markers that were not
previously identiﬁed in other GWAS. We identiﬁed hap-
lotype blocks using a feature available in the software,
using the default parameters—maximum length of 160 kb
and maximum of 30 markers per block. A haplotype
association analysis was performed in a case–control set-
ting to improve statistical power. We selected the markers
that showed statistical signiﬁcance (p\0.001) in both (1)
allelic and haplotype association analyses, with each
identiﬁed block containing more than two SNPs and (2)
chose representative SNPs with r
2 C 0.8. After applying
these selection criteria, we selected 35 SNPs for replication
in Stage II with a completely independent series of 1,153
cases and 1,215 controls. Association analysis and tests of
signiﬁcance were carried out independently for Stage II
and in combined samples from Stages I and II (potential
combined sample size of 2,991 from cases and controls left
for association analysis following data ﬁltering criteria
described above).
Results
GWAS in 348 cases and 348 controls (Stage I)
Allelic association analysis with 782,838 SNPs showed
statistically signiﬁcant (p\0.05) differences between the
cases and the controls at multiple genomic locations
(35,859 SNPs) scattered across all chromosomes (Fig. 1).
We explored multi-dimensional scaling using PCA-based
method. Case and control samples of this study showed
signiﬁcant overlap with the Central European population
cluster of HapMap samples on PCA plots (Supplementary
Figure S1). It indicates that our predominantly Caucasian
population has (1) high genetic similarity with the Euro-
pean population when compared with the Asian or Yoruba
Indians (African) and (2) the cases and the controls from
the Alberta region showed near genetic homogeneity, i.e.,
both appear to be of eastern European ancestry. Quantile–
quantile plot showed that most of the observed associations
lie along the line of best ﬁt (expected distribution) con-
forming to the null hypothesis of no association for
majority of the SNPs (Supplementary Figure S2).
Replication of markers from Stage I in independent
study (Stage II)
In Stage II, we genotyped 35 SNPs using Sequenom Mass-
ARRAY iPlex technology in independent case and control
subjects (1,153 cases and 1,215 controls). We also per-
formed a joint analysis which is considered the best way to
confer power and conﬁdence in the results, as well as to
address the possible sampling bias and inherent heteroge-
neity of breast cancer as a phenotype (Skol et al. 2006).
The joint analysis consisted of a total of 1,455 breast
cancer cases and 1,536 controls obtained by combining the
samples from the two stages of the study. Of the 35 SNPs
considered for replication, 6 SNPs showed statistical sig-
niﬁcance in all stages (Stages I and II) and in joint analysis
(Table 1). The data from the remaining 29 SNPs are
summarized in Supplementary Table S1. Data summarized
in Table 1 also lists the OR, 95% CI, false discovery rate
(FDR), SNP call rate and MAF for the six signiﬁcant
polymorphisms described above.
The polymorphisms with high signiﬁcance (10
-6–10
-4)
in joint analysis and conferring risk for breast cancer are in
chromosomes 4, 5, 16 and 19. Of these, rs1092913 is
located on chromosome 5p15.2 [p value 1.89 9 10
-6, FDR
3.30 9 10
-5, OR (95% CI) 1.45 (1.24–1.69)], with the
ropporin-1-like (ROPN1L) gene present 2.5 kb downstream
532 Hum Genet (2011) 130:529–537
123of the polymorphism; the three SNPs present on chromo-
some 19q13.33, ZNF577 (zinc ﬁnger protein 577) gene are
(1) rs10411161 (p value 7.09 9 10
-6, FDR 8.27 9 10
-5)
located in the 30 untranslated region (UTR; 2.8 kb down-
stream of the stop codon, Goldenpath-hg 18/db SNP build
130), (2) rs3848562 (p value 9.23 9 10
-6, FDR
8.08 9 10
-5) and (3) rs11878583 (p value 1.35 9 10
-4,
FDR 9.45 9 10
-4) located in the introns 6 and 2, respec-
tively. We observed ORs (95% CI) of 1.42 (1.22–1.65),
1.42 (1.22–1.66) and 1.35 (1.16–1.57), respectively, for the
three ZNF577 SNPs. However, rs10411161 showed devia-
tion from HWE in the Stage II sample set and in the joint
analysis for both cases and controls. We ruled out the
obvious possibility of genotyping errors, and both Stage I
and Stage II samples (with several replicates) showed good
concordance within and across the genotyping platforms
(see ‘‘Materials and methods’’). The ﬁfth SNP, rs1429142,
is located on chromosome 4q31.23 (p value 3.59 9 10
-4,
FDR 2.10 9 10
-3), with EDNRA (endothelin receptor type
A) gene present approximately 112.5 kb downstream of the
polymorphism. An OR of 1.27 (95% CI 1.11–1.45) was
noted for the minor allele C. Finally, rs1981867 located on
chromosome 16q23.2 showed satisfactory statistical sig-
niﬁcance in Stage I (p value 3.7 9 10
-4) and in joint
analysis (p value 4.32 9 10
-4, FDR 2.16 9 10
-3) but
showed only marginal signiﬁcance in Stage II (p value
0.03). An OR of 1.22 (95% CI 1.09–1.36) for the minor
allele A was noted.
Discussion
Increasingly, assessing genetic risk in complex traits
requires identiﬁcation of multiple loci conferring risk and/
or mining of the data in an integrated manner to identify
potential gene–gene interactions that together may explain
a higher proportion of risk than the single-locus analysis
(Park et al. 2010; Yang et al. 2010). This approach calls for
identiﬁcation of potential novel risk-associated SNPs and
their subsequent validation to improve the accuracy of
genetic risk assessment models. We performed a whole
genome analysis to identify novel markers (single-locus
analysis) associated with breast cancer and conﬁrmed
several new loci in a larger, independent replication set of
cases and controls. None of these six SNPs were signiﬁcant
after genome-wide correction in individual stages or in the
joint analysis from the two-stage association study pre-
sented here.
Fig. 1 Manhattan plot for Stage I association study showing 35,589 markers (p\0.05) distributed across chromosomes. This graph is plotted
against allelic v
2 p values on –log10 scale to indicate polygenic nature of breast cancer susceptibility
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123The conduct of our study was appropriate, in that the
sample size used in our Stage I GWAS (348 cases and 348
controls) closely matched those used in Stage I of earlier
studies, e.g., 390 familial breast cancer cases and 364
controls used by Easton et al. (2007) and 249 Ashkenazi
Jew familial cases and 299 controls used by Gold et al.
(2008). Furthermore, this was only the second study, after
Zheng et al. (2009), to use high-density Affymetrix SNP
arrays (906,600 SNPs/array), which provides a vast phys-
ical coverage of the genome in an unbiased manner, to
identify the markers associated with disease susceptibility.
A precedent exists for using high-density SNP arrays to
identify breast cancer susceptibility loci and to subse-
quently replicate those identiﬁed variants in large cohorts
(Ahmed et al. 2009; Easton et al. 2007; Gold et al. 2008;
Hunter et al. 2007; Murabito et al. 2007; Stacey et al. 2007,
2008; Thomas et al. 2009; Turnbull et al. 2010; Zheng et al.
2009). The SNPs identiﬁed, so far, in GWAS including our
study were largely surrogate markers; ﬁne mapping and
independent validation studies are underway to identify
causal variants.
Using the cohorts described here, we successfully vali-
dated the FGFR2 polymorphisms (data not shown), which
were also highly reproducible in several cohorts and dis-
ease models (Raskin et al. 2008; Rebbeck et al. 2009;
Thomas et al. 2009; Turnbull et al. 2010; Zheng et al.
2009). In this study, we report six putative candidate loci,
and further large-scale studies are required to conﬁrm their
association with breast cancer. These include SNP
rs1981867 in the open reading frame on chromosome 16
(C16orf61), a gene that has been shown to be associated
with multi-drug resistance (Campone et al. 2008). Easton
et al. (2007) and Stacey et al. (2007) previously reported
that rs3803662 positioned on chromosome 16q is associ-
ated with breast cancer risk in two independent GWAS.
The identiﬁed SNP rs1981867 in this study from chromo-
some 16 further emphasizes the importance of this region
in breast cancer. While these results and interpretations
require large-scale studies and independent conﬁrmation,
repeated and independent observations by several research
groups suggesting breast cancer risk related to these open
reading frames underscores the importance of this region.
Functional characterization of these variants is warranted.
Zinc ﬁnger proteins are commonly involved in tran-
scriptional regulation of genes. Tan et al. (2004b) have
shown that C-terminal transcriptional repression domain of
zinc ﬁnger protein ZBRK1 interacts with BRCA1 tumor
suppressor gene to repress transcription. Previous linkage
studies have shown that mutations in BRCA1 gene are a
common event in early-onset, multiple-case breast cancer
families (Hall et al. 1990). The C-terminal extension of
ZNF577 shares sequence homology with ZBRK1 (Tan
et al. 2004a). It remains to be determined whether ZNF577
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123identiﬁed in our study also plays a role in transcriptional
repression by binding to the BRCA1 protein. We found
three SNPs from ZNF577 gene region to be associated with
disease susceptibility: rs10411161 (only SNP in the repli-
cation stage that showed deviation from HWE) found
2.8 kb downstream of the gene in the 30 UTR, and the other
two markers rs3848562 and rs11878583 are present in the
introns 2 and 6, respectively. The reasons for the deviation
of the 30 UTR SNP in ZNF577 gene require further scrutiny
and validation from independent studies. Similarly, a
recent GWAS has shown a polymorphism rs10995190
located within the intron 4 of zinc ﬁnger protein 365
(ZNF365) to be associated with breast cancer susceptibility
(Turnbull et al. 2010). Further studies are required to
understand the functional role of ZNF577.
The endothelin receptor type A (EDNRA) gene is loca-
ted 112.5 kb upstream of the polymorphism rs1981867,
which we identiﬁed in our association study. Its role in
breast cancer susceptibility requires further attention.
Interestingly, constitutive co-expression of endothelin-1
growth factor and EDNRA often results in ovarian carci-
noma (Salani et al. 2000) and also contributes to bone
metastases in different primary tumors (Medinger et al.
2003).
The ROPN1L gene on chromosome 5p15.2 is present
2.5 kb downstream of the polymorphism rs1092913. There
is no previous evidence on the association of the gene to
breast cancer susceptibility. The ROPN1L gene encodes for
a sperm protein known to interact with A-kinase anchoring
protein (GeneCards 2010). It is evident from previous
GWAS that the p arm of chromosome 5 harbors several
polymorphisms implicated in breast cancer susceptibility
(Stacey et al. 2008; Thomas et al. 2009). Moreover, Lowe
et al. (2007) showed that ROPN1L gene is highly expressed
in pancreatic cancer when compared to the normal pan-
creatic tissues and other tumors in their dataset. Again, our
results motivate further investigation in this gene.
Conclusion
We report six candidate polymorphisms that were not
previously associated with breast cancer risk in Caucasian
population from Alberta. These ﬁndings merit further
replication and, if conﬁrmed, warrant ﬁne mapping and
functional validation studies.
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